p,p-hydroxy-curucuminCAS# 52328-96-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 52328-96-8 | SDF | Download SDF |
PubChem ID | 5324473 | Appearance | Powder |
Formula | C19H16O4 | M.Wt | 308.3 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxyphenyl)hepta-1,4,6-trien-3-one | ||
SMILES | C1=CC(=CC=C1C=CC(=CC(=O)C=CC2=CC=C(C=C2)O)O)O | ||
Standard InChIKey | YXAKCQIIROBKOP-HSSGTREWSA-N | ||
Standard InChI | InChI=1S/C19H16O4/c20-16-7-1-14(2-8-16)5-11-18(22)13-19(23)12-6-15-3-9-17(21)10-4-15/h1-13,20-22H/b11-5+,12-6+,18-13- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
p,p-hydroxy-curucumin Dilution Calculator
p,p-hydroxy-curucumin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.2436 mL | 16.218 mL | 32.4359 mL | 64.8719 mL | 81.0898 mL |
5 mM | 0.6487 mL | 3.2436 mL | 6.4872 mL | 12.9744 mL | 16.218 mL |
10 mM | 0.3244 mL | 1.6218 mL | 3.2436 mL | 6.4872 mL | 8.109 mL |
50 mM | 0.0649 mL | 0.3244 mL | 0.6487 mL | 1.2974 mL | 1.6218 mL |
100 mM | 0.0324 mL | 0.1622 mL | 0.3244 mL | 0.6487 mL | 0.8109 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Vindorosine
Catalog No.:BCN5668
CAS No.:5231-60-7
- Anisatin
Catalog No.:BCC8118
CAS No.:5230-87-5
- Flavoglaucin
Catalog No.:BCN6398
CAS No.:523-73-9
- Evolitrine
Catalog No.:BCN8350
CAS No.:523-66-0
- Angelicin
Catalog No.:BCN5669
CAS No.:523-50-2
- 4-Amino-2,5-dimethoxy-N-phenylbenzenesulphonamide
Catalog No.:BCC8676
CAS No.:52298-44-9
- Ginsenoside Rg2
Catalog No.:BCN1067
CAS No.:52286-74-5
- Ginsenoside Re
Catalog No.:BCN1073
CAS No.:52286-59-6
- Ginsenoside Rf
Catalog No.:BCN1075
CAS No.:52286-58-5
- 3,5-Diprenyl-4-hydroxybenzaldehyde
Catalog No.:BCN4624
CAS No.:52275-04-4
- CGP 57380
Catalog No.:BCC5279
CAS No.:522629-08-9
- Isomucronulatol
Catalog No.:BCN1428
CAS No.:52250-35-8
- Tetramethylcurcumin
Catalog No.:BCN2746
CAS No.:52328-97-9
- Dimethylcurcumin
Catalog No.:BCN2748
CAS No.:52328-98-0
- 6alpha-Chloro-5beta-hydroxywithaferin A
Catalog No.:BCN8007
CAS No.:52329-20-1
- Alnusone
Catalog No.:BCN8108
CAS No.:52330-11-7
- 2-Benzoyl-1,3,4,4a,5,8a-hexahydro-6(2H)-isoquinolinone
Catalog No.:BCC8559
CAS No.:52346-14-2
- Erysotramidine
Catalog No.:BCN5670
CAS No.:52358-58-4
- Epistephamiersine
Catalog No.:BCN5671
CAS No.:52389-15-8
- Wedelolactone
Catalog No.:BCN5672
CAS No.:524-12-9
- gamma-Fagarine
Catalog No.:BCN5673
CAS No.:524-15-2
- Dauricine
Catalog No.:BCN4977
CAS No.:524-17-4
- Fraxin
Catalog No.:BCN1237
CAS No.:524-30-1
- 2-APB
Catalog No.:BCC6978
CAS No.:524-95-8
Dietary Turmeric Bisdemethoxycurcumin Suppresses Wilms' Tumor 1 and CD34 Protein Expressions in KG-1a Leukemic Stem Cells.[Pubmed:30955364]
Nutr Cancer. 2019 Apr 7:1-12.
Leukemic cells remaining in the body is the main problem for cancer patients, and these cells are called Leukemic Stem Cells (LSCs). Many studies have revealed that the overexpression of the Wilms' tumor 1 (WT1) protein is related to leukemogenesis. Curcuminoids (curcumin, demethoxycurcumin, and bisdemethoxycurcumin) from Thai turmeric (Curcuma longa Linn.) are the focus of this study because they have been previously been reported to show potent antileukemic activity. This study aims to investigate the cytotoxic effect of in-house curcuminoids on the human leukemic stem cell line (KG-1a) when compared to other leukemic cell lines (KG-1 and K562). MTT assays were used to determine the cytotoxicity of curcuminoids at various concentrations. Curcumin exhibited the strongest cytotoxic activity on KG-1a cells with IC50 values of 13.6 +/- 1.9 microM. To determine the effect of curcuminoids on WT1 and CD34 protein expressions by Western blotting, KG-1a cells were treated with noncytotoxic concentrations (IC20 value). Bisdemethoxycurcumin showed the strongest suppression of WT1 and CD34 protein expressions with 73.3 +/- 1.4 and 82.9 +/- 2.0%, respectively. In summary, curcuminoids, especially bisdemethoxycurcumin, could inhibit WT1 and CD34 protein expressions. Thus, bisdemethoxycurcumin is a compound that calls for further studies of its process in the inhibition of WT1 and CD34 expressions in LSCs for the leukemia treatment.
Bisdemethoxycurcumin protects against renal fibrosis via activation of fibroblast apoptosis.[Pubmed:30660576]
Eur J Pharmacol. 2019 Mar 15;847:26-31.
Renal fibrosis is the common final outcome of nearly all progressive chronic kidney diseases (CKD) that eventually develop into end-stage renal failure, which threatens the lives of patients. Currently, there are no effective drugs for the treatment of renal fibrosis. However, studies have shown that certain plant natural products have a fibrosis-alleviating effect. Thus, we have screened a large number of natural products for their ability to protect against renal fibrosis and found that bisdemethoxycurcumin has a good therapeutic effect in renal fibrosis according to the data obtained in a mouse model of unilateral ureteral obstruction (UUO). The results indicate that bisdemethoxycurcumin can efficiently attenuate renal fibrosis induced by UUO. Additional studies of the bisdemethoxycurcumin mechanism of action in the treatment of renal fibrosis demonstrated that the therapeutic effect of bisdemethoxycurcumin is mediated by the specific induction of fibroblast apoptosis at a concentration of 20muM. bisdemethoxycurcumin can efficiently protect against renal fibrosis both in vitro and in vivo. This discovery will provide new ideas for renal fibrosis treatment in clinics and a new direction for the development of effective drug therapy of renal fibrosis.
Efflux excretion of bisdemethoxycurcumin-O-glucuronide in UGT1A1-overexpressing HeLa cells: Identification of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins 1 (MRP1) as the glucuronide transporters.[Pubmed:30334318]
Biofactors. 2018 Nov;44(6):558-569.
Bisdemethoxycurcumin (BDMC) was a natural curcuminoid with many bioactivities present in turmeric (Curcuma longa L.). However, the disposition mechanisms of BDMC via uridine 5'-diphospho-glucuronosyltransferase (UGT) metabolism still remain unclear. Therefore, we aimed to determine the potential efflux transporters for the excretion of BDMC-O-glucuronide. Herein, chemical inhibition assays (Ko143, MK571, dipyridamole, and leukotriene C4) and biological inhibition experiments including stable knocked-down of breast cancer resistance protein (BCRP), multidrug resistance-associated proteins (MRPs) transporters were both performed in a HeLa cell line stably overexpressing UGT1A1 established previously. The results indicated that Ko143 (5 and 20 muM) caused a marked reduction in excretion rate (18.4-55.6%) and elevation of intracellular BDMC-O-glucuronide (28.8-48.1%), whereas MK-571 (5 and 20 muM) resulted in a significant decrease in excretion rate (6.2-61.6%) and increase of intracellular BDMC-O-glucuronide (maximal 27.1-32.6%). Furthermore, shRNA-mediated silencing of BCRP transporter led to a marked reduction in the excretion rate (21.1-36.9%) and an obvious elevation of intracellular glucuronide (24.9%). Similar results were observed when MRP1 was partially silenced. In addition, MRP3 and MRP4 silencing both displayed no obvious changes on the excretion rate and intracellular levels of glucuronide. In conclusion, chemical inhibition and gene silencing results both indicated that generated BDMC-O-glucoside were excreted primarily by the BCRP and MRP1 transporters. (c) 2018 BioFactors, 44(6):558-569, 2018.
Inhibitory effects of bisdemethoxycurcumin on mast cell-mediated allergic diseases.[Pubmed:30316076]
Int Immunopharmacol. 2018 Dec;65:182-189.
Most allergic reactions are induced by mast cell activation. Mast cells play vital roles in the pathogenesis of allergic diseases. Bisdemethoxycurcumin (BDMC), a natural curcuminoid, has potential anti-allergic effects. Hence, we explored the effect of BDMC on mast cell-mediated allergic diseases. The study proved that BDMC suppresses beta-hexosaminidase release, granule release, and membrane ruffling in monoclonal anti-2,4,6-dinitrophenyl-immunoglobulin (Ig) E/human serum albumin (DNP-IgE/HSA)-stimulated rat basophilic leukaemia cells (RBL-2H3 cells), and BDMC suppressed ovalbumin (OVA)-induced allergic rhinitis (AR) symptoms and OVA-specific IgE levels in AR mice. Furthermore, BDMC increased the survival of compound 48/80 anaphylaxis shock mice and elevated the decreased rectal temperature in OVA-induced active systemic anaphylaxis mice. These findings indicate that BDMC regulates the degranulation of mast cells, demonstrating its potential in the treatment of mast cell-induced allergic reactions.